Contributed commentary by six-year cancer survivor Jessica Baladad on health care costs and the 340B Drug Pricing Program.

Sociologist Carole Joffe and law professor David Cohen explore a major reason why in their new book " After Dobbs: How the ...

Lumping cannabis in with drugs considered to have no medical value undermines patient access in Maine and beyond.

Will the electronic patient file soon be filled throughout Germany? The Federal Ministry of Health at least hopes so and has ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...

As 23andMe files bankruptcy to facilitate the company's sale, some worry whether customers' genetic data will stay secure ...

The future of pharmaceutical investment lies in the convergence of ESG principles with a strong emphasis on positive social ...

At a time when Ohio is facing an ongoing health crisis, Gov. Mike DeWine has chosen ideology over public health, ...

Goba Care in Edmonton provides assistance, advocacy, and cultural connection at no cost to northern residents travelling ...

Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We ...

Michael Fosina began serving as president of Calvary Hospital in New York City in January, bringing decades of healthcare ...

A growing mistrust of medical providers could be traced back to doubts about scientific validity and treatment costs, ...